Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

Best Practice & Research Clinical Endocrinology & Metabolism(2009)10.1016/j.beem.2009.03.008Source: DataRank Database

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results is a research paper published in Best Practice & Research Clinical Endocrinology & Metabolism (2009). On theSindex it has a DataRank of 7.0. It has been cited 127 times, with 119 citing works in its 1-hop citation network.

N/A

7.0DataRank · unranked

Scored on demand from live citation data

127 citations · 119 citing works in its network

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 6.79)OA: closedTopics (51)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 10%Citation Network 90%

Base Score Contribution

0.728

From this paper's citation signal

Citation Network Contribution

6.3

From 106 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 119 citers.

Liraglutide for weight loss in obese people – Authors' reply
The Lancet20105 citations3 referencesContributes 0.597
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Diabetes Care2012218 citations21 referencesContributes 0.257
Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein
Diabetes/Metabolism Research and Reviews2010297 citations24 referencesContributes 0.237
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)
Diabetic Medicine2013143 citations21 referencesContributes 0.237
Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2
Diabetes20112,290 citations34 referencesContributes 0.228

Authors (1)

Sten Madsbad ORCID

Live enrichment

PubMed:19748064 OpenAlex:https://openalex.org/W2045849794

Abbott Laboratories

Novo Nordisk

Sanofi

FWCI

6.79

Citation Percentile

1.0%

Citation Trend

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2024

2025

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S1521690X0900027X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1521690X0900027X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.beem.2009.03.008

repositoryhttps://pubmed.ncbi.nlm.nih.gov/19748064

repositoryhttps://researchprofiles.ku.dk/da/publications/90e56310-aabc-11df-928f-000ea68e967b

Fields of Study

Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerPancreatic function and diabetesAnti-Obesity AgentsClinical Trials as TopicClinical Trials, Phase II as TopicDelayed-Action PreparationsDiabetes Mellitus, Type 2ExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansLiraglutidePeptidesReceptors, GlucagonVenoms

MeSH Terms

Glucagon-Like Peptide-1 ReceptorLiraglutideExenatideClinical Trials as TopicDelayed-Action PreparationsDiabetes Mellitus, Type 2Glycated HemoglobinHumansPeptidesVenomsClinical Trials, Phase II as TopicReceptors, GlucagonAnti-Obesity AgentsGlucagon-Like Peptide 1

Keywords

ExenatideLiraglutideGlucagon-like peptide 1 receptorIncretinType 2 diabetesMedicineEndocrinologyAgonistInternal medicineGastric emptyingNauseaGlucagon-like peptide-1VildagliptinWeight lossDiabetes mellitusLixisenatidePharmacologyReceptorObesityStomach

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (2)

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) study: Rationale, design and baseline characteristics of a randomized control trial of the MIND diet on cognitive decline

N/A

3.1DataRank · unranked

Contemporary Clinical Trials(2021)

co-cited

10.1016/j.cct.2021.106270

Slc12a8 is a nicotinamide mononucleotide transporter

N/A

8.5DataRank · unranked

Nature Metabolism(2019)

co-cited

10.1038/s42255-018-0009-4

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (1)

Funding (3 grants)

Impact

Open Access

Topics

Related Papers (2)